By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aclaris Therapeutics 

101 Lindenwood Drive
Suite 400
Malvern  Pennsylvania  19355  U.S.A.
Phone: 484-324-7933 Fax: 484-324-7949



Company News
Aclaris (ACRS) To Ring The Nasdaq Stock Market Closing Bell 7/25/2016 8:54:42 AM
Aclaris (ACRS) Completes Enrollment Of Phase 3 Pivotal Trials Of A-101 For The Treatment Of Seborrheic Keratosis (SK); Provides Update On Clinical Programs 7/25/2016 8:53:45 AM
Aclaris (ACRS) Appoints Kevin Scott As Vice President Of Sales 5/5/2016 8:09:10 AM
Aclaris (ACRS) Initiates Phase II Clinical Trial Of A-101 For Treatment Of Common Warts 12/7/2015 7:43:30 AM
Aclaris (ACRS) Reports Third Quarter 2015 Financial Results 11/19/2015 8:12:02 AM
Aclaris (ACRS) Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares 10/14/2015 10:31:44 AM
Aclaris (ACRS) Closes $56.5M IPO 10/14/2015 8:45:52 AM
Aclaris (ACRS) Announces Pricing Of IPO 10/7/2015 7:24:16 AM
Aclaris Therapeutics Sets Terms for $75 Million IPO 9/28/2015 6:59:34 AM
Aclaris Therapeutics Nabs $40 Million, Strikes Skin Disorders Pact with Rigel (RIGL) 9/9/2015 11:02:21 AM